Grifols, S.A. (GRFS)

Nasdaq · Healthcare · Drug Manufacturers - General
$8.15-0.61%As of 2026-11-22 · USD
Last session low $8.08Last session high $8.22
52-week low $6.9652-week high $9.77
Market cap
$5.55B
Sector
Healthcare
P/E (TTM)
9.8x
Dividend yield
1.30%

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-19 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)48.0In the neutral range (30 to 70)
MACD (12, 26, 9)0.22Below its signal line (0.27); histogram -0.05
Bollinger %B (20, 2)31%Inside the bands (7.74 to 9.08)
SMA 208.41Price is 3.1% below
SMA 507.81Price is 4.4% above
SMA 2007.96Price is 2.4% above
ATR (20)2.82% of priceAverage true range per day
52-week position42%In the middle of the 6.96 to 9.77 range

About Grifols, S.A.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others.

Latest fiscal yearEnded 2025-12-31: revenue of 7.52B EUR and an operating margin of 16.6%.

More in Drug Manufacturers - General